316 related articles for article (PubMed ID: 16603730)
1. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.
Camilleri M; Bharucha AE; Ueno R; Burton D; Thomforde GM; Baxter K; McKinzie S; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G942-7. PubMed ID: 16603730
[TBL] [Abstract][Full Text] [Related]
2. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study.
Esfandyari T; Camilleri M; Ferber I; Burton D; Baxter K; Zinsmeister AR
Neurogastroenterol Motil; 2006 Sep; 18(9):831-8. PubMed ID: 16918762
[TBL] [Abstract][Full Text] [Related]
3. Lubiprostone: a chloride channel activator.
Lacy BE; Levy LC
J Clin Gastroenterol; 2007 Apr; 41(4):345-51. PubMed ID: 17413599
[TBL] [Abstract][Full Text] [Related]
4. Lubiprostone: a chloride channel activator for treatment of chronic constipation.
Ambizas EM; Ginzburg R
Ann Pharmacother; 2007 Jun; 41(6):957-64. PubMed ID: 17519292
[TBL] [Abstract][Full Text] [Related]
5. Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study.
Hooks SB; Rutland TJ; Di Palma JA
Gastrointest Endosc; 2009 Nov; 70(5):942-6. PubMed ID: 19577749
[TBL] [Abstract][Full Text] [Related]
6. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Johanson JF; Ueno R
Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
[TBL] [Abstract][Full Text] [Related]
7. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects.
Sweetser S; Busciglio IA; Camilleri M; Bharucha AE; Szarka LA; Papathanasopoulos A; Burton DD; Eckert DJ; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G295-301. PubMed ID: 19033530
[TBL] [Abstract][Full Text] [Related]
8. Lubiprostone: chloride channel activator for chronic constipation.
Rivkin A; Chagan L
Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers.
Choung RS; Talley NJ; Peterson J; Camilleri M; Burton D; Harmsen WS; Zinsmeister AR
Neurogastroenterol Motil; 2007 Mar; 19(3):180-7. PubMed ID: 17300287
[TBL] [Abstract][Full Text] [Related]
10. Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation.
Crowell MD; Harris LA; DiBaise JK; Olden KW
Curr Opin Investig Drugs; 2007 Jan; 8(1):66-70. PubMed ID: 17263187
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans.
Bouras EP; Burton DD; Camilleri M; Stephens DA; Thomforde GM
Neurogastroenterol Motil; 2004 Dec; 16(6):729-35. PubMed ID: 15601422
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers.
Talley NJ; Camilleri M; Burton D; Thomforde G; Koch K; Rucker MJ; Peterson J; Zinsmeister AR; Earnest DL
Aliment Pharmacol Ther; 2006 Sep; 24(5):859-67. PubMed ID: 16918891
[TBL] [Abstract][Full Text] [Related]
13. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.
Castillo EJ; Delgado-Aros S; Camilleri M; Burton D; Stephens D; O'Connor-Semmes R; Walker A; Shachoy-Clark A; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2004 Aug; 287(2):G363-9. PubMed ID: 15246968
[TBL] [Abstract][Full Text] [Related]
15. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
Johanson JF; Morton D; Geenen J; Ueno R
Am J Gastroenterol; 2008 Jan; 103(1):170-7. PubMed ID: 17916109
[TBL] [Abstract][Full Text] [Related]
18. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
19. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
Saad R; Chey WD
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):497-508. PubMed ID: 19072397
[TBL] [Abstract][Full Text] [Related]
20. Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
O'Brien CE; Anderson PJ; Stowe CD
Ann Pharmacother; 2010 Mar; 44(3):577-81. PubMed ID: 20179256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
